In Vitro Postantibiotic Effects of Rifapentine, Isoniazid, and Moxifloxacin against Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 1, 2004, Pages 340-343

  Chan, Chiu Yeung ^a   Au Yeang, Carrie ^a   Yew, Wing Wai ^b   Leung, Chi Chiu ^c   Cheng, Augustine F B ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b GRANTHAM HOSPITAL   (Hong Kong)

^c DEPARTMENT OF HEALTH   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; MOXIFLOXACIN; RIFAPENTINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; RADIOMETRY;

ANTI-INFECTIVE AGENTS; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; DRUG COMBINATIONS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; QUINOLINES; RIFAMPIN;

EID: 0346731290     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.1.340-343.2004     Document Type: Article

References (24)

1. Benator, D., M. Bhattacharya, L. Bozeman, W. Burman, A. Cantazaro, R. Chaisson, F. Gordin, C. R. Horsburgh, J. Horton, A. Khan, C. Lahart, B. Metchock, C. Pachucki, L. Stanton, A. Vernon, M. E. Villarino, Y. C. Wang, M. Weiner, S. Weis, et al. 2002. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360: 528-534.
2. Bock, N. N., T. R. Sterling, C. D. Hamilton, C. Pachucki, Y. C. Wang, D. S. Conwell, A. Mosher, M. Samuels, A. Vernon, et al. 2002. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am. J. Resp. Crit. Care Med. 165:1526-1530.
3. Bundtzen, R. W., A. U. Gerber, D. L. Cohn, and W. A. Craig. 1981. Post-antibiotic suppression of bacterial growth. Rev. Infect. Dis. 3:28-37.
4. Burkhardt, O., K. Borner, H. Stass, G. Beyer, M. Allewelt, C. E. Nord, and H. Lode. 2002. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. Scand. J. Infect. Dis. 34: 898-903.
5. Burman, W. J., K. Gallicano, and C. Peloquin. 2001. Comparative pharmcokinetics and pharmacodynamics of the rifamycin antibacterials. Clin. Pharmacokinet. 40:327-341.
6. Chan, C. Y., C. Au-Yeang, W. W. Yew, M. Hui, and A. F. B. Cheng. 2001. Postantibiotic effects of antituberculosis agents alone and in combination. Antimicrob. Agents Chemother. 45:3631-3634.
7. Conte, J. E., Jr., J. A. Golden, M. McQuitty, J. Kipps, E. T. Lin, and E. Zurlinden. 2000. Single-dose intrapulmonary pharmacokinetics of rifapentine in normal subjects. Antimicrob. Agents Chemother. 44: 985-990.
8. Craig, W. A., and S. C. Ebert. 1990. Killing and regrowth of bacteria in vitro: a review. Scand. J. Infect. Dis. Suppl. 74:63-70.
9. Dickinson, J. M., and D. A. Mitchison. 1968. In vitro and in vivo studies to assess the suitability of antituberculous drugs for use in intermittent chemotherapy regimens. Tubercle Suppl. 49:66-70.
10. Dickinson, J. M., and D. A. Mitchison. 1970. Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis. Tubercle 51:389-396.
11. Dickinson, J. M., and D. A. Mitchison. 1970. Suitability of rifampicin for intermittent administration in the treatment of tuberculosis. Tubercle 51: 82-94.
12. Dickinson, J. M., G. A. Ellard, and D. A. Mitchison. 1968. Suitability of isoniazid and ethambutol for intermittent administration in the treatment of tuberculosis. Tubercle 49:351-366.
13. Fox, W. 1981. Whither short course chemotherapy? Br. J. Dis. Chest 75:331-357.
14. Fuursted, K. 1997. Evaluation of the post-antibiotic effect of six anti-mycobacterial agents against Mycobacterium avium by the Bactec radiometric method. J. Antimicrob. Chemother. 40:33-38.
15. Hu, Y., A. R. Coates, and D. A. Mitchison. 2003. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:653-657.
16. Inderlied, C. B., L. S. Young, and J. K. Yamada. 1987. Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial gents by various methods. Antimicrob. Agents Chemother. 31:1697-1702.
17. Lettieri, J., R. Vargas, V. Agarwal, and P. Liu. 2001. Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400 mg in healthy male volunteers. Clin. Pharmaokinet. 40(Suppl. 1):19-25.
18. Lounis, N., A. Bentoucha, C. Truffot-Pernot, B. Ji, R. J. O'Brien, A. Vernon, G. Roseigno, and J. Grosset. 2001. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob. Agents Chemother. 45:3482-3486.
19. Marshall, J. D., S. Abdel-Rahman, K. Johnson, R. E. Kauffman, and G. L. Kearns. 1999. Rifapentine pharmacokinetics in adolescents. Pediatr. Infect. Dis. J. 18: 882-888.
20. Peloquin, C. A. 1997. Using therapeutic drug monitoring to dose the anti-mycobacterial drugs. Clin. Chest Med. 18:79-87.
21. Stass, H., and D. Kubitza. 2001. Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone in humans. Clin. Pharmacokinet. 40(Suppl. 1):57-62.
22. Tam, C. M., S. L. Chan, K. M. Kam, E. Sim, D. Staples, K. M. Sole, H. Al-Glusein, and D. A. Mitchison. 2000. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Interim report: no activity of isoniazid in the continuation phase. Int. J. Tuberc. Lung Dis. 4:262-267.
23. Tam, C. M., S. L. Chan, K. M. Kam, R. L. Goodall, and D. A. Mitchison. 2002. Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. Int. J. Tuberc. Lung Dis. 6:3-10.
24. Vogelman, B. S., and W. A. Craig. 1985. Postantibiotic effects. J. Antimicrob. Chemother. 15(Suppl. A):37-46.